Envíos recientes

Delphi consensus for the third-line treatment of metastatic colorectal cancer

Vera, Ruth; Rivera, Fernando; García-Alfonso, Pilar; Aranda Aguilar, Enrique; Elez, Elena (Springer, 2024-06)

Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti–PD-L1, for BRCA wild-type, platinum-sensitive, recurrent ovarian cancer

Mutch, David; Voulgari, Athina; Chen, Xian (Marissa); Bradley, William; Pérez-Fidalgo, J. Alejandro; OAKNIN, ANA (Wiley, 2024-06-01)

Immune-monitoring of myelodysplastic neoplasms: Recommendations from the i4MDS consortium

Tentori, Cristina A.; Zhao, Lin P.; Tinterri, Benedetta; Strange, Kathryn; Zoldan, Katharina; Dimopoulos, Konstantinos; Gallur, Laura; VALCARCEL, DAVID (Wiley, 2024-05-15)

CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials

Segal, Neil H.; MELERO BERMEJO, IGNACIO; Moreno, Victor; Steeghs, Neeltje; marabelle, aurelien; Rohrberg, Kristoffer; Argilés, Guillem; Tabernero, Josep (Nature Portfolio, 2024-05-15)

The TP53-activated E3 ligase RNF144B is a tumour suppressor that prevents genomic instability

ABAD, ETNA; Sandoz, Jeremy; Romero Sola, Gerard; Zadra, Ivan; Urgel-Solas, Julia; Borredat, Pablo (BioMed Central, 2024-04-29)

Scientia. Depósito de Información Digital del Departamento de Salud

VHIO - Articles científics: Envíos recientes

Delphi consensus for the third-line treatment of metastatic colorectal cancer

Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti–PD-L1, for BRCA wild-type, platinum-sensitive, recurrent ovarian cancer

Immune-monitoring of myelodysplastic neoplasms: Recommendations from the i4MDS consortium

CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials

The TP53-activated E3 ligase RNF144B is a tumour suppressor that prevents genomic instability

Scientia. Depósito de Información Digital del Departamento de Salud

VHIO - Articles científics: Envíos recientes

Delphi consensus for the third-line treatment of metastatic colorectal cancer ﻿

Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti–PD-L1, for BRCA wild-type, platinum-sensitive, recurrent ovarian cancer ﻿

Immune-monitoring of myelodysplastic neoplasms: Recommendations from the i4MDS consortium ﻿

CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials ﻿

The TP53-activated E3 ligase RNF144B is a tumour suppressor that prevents genomic instability ﻿

Delphi consensus for the third-line treatment of metastatic colorectal cancer

Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti–PD-L1, for BRCA wild-type, platinum-sensitive, recurrent ovarian cancer

Immune-monitoring of myelodysplastic neoplasms: Recommendations from the i4MDS consortium

CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials

The TP53-activated E3 ligase RNF144B is a tumour suppressor that prevents genomic instability